Protein Panel of Serum-Derived Small Extracellular Vesicles for the Screening and Diagnosis of Epithelial Ovarian Cancer

• Published in: Cancers Vol. 14; no. 15; p. 3719
• Main Authors: Lai, Huiling, Guo, Yunyun, Tian, Liming, Wu, Linxiang, Li, Xiaohui, Yang, Zunxian, Chen, Shuqin, Ren, Yufeng, He, Shasha, He, Weipeng, Yang, Guofen
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 30.07.2022; MDPI
• Subjects: Antigens; Apolipoproteins; Biomarkers; Cancer screening; Chromatography; Differential diagnosis; extracellular vesicle; Extracellular vesicles; Fatalities; Fibrinogen; Malignancy; Medical prognosis; Medical screening; Metastasis; Microscopy; Mucin; Ovarian cancer; ovarian cancer screening; Patients; Proteins; Proteomics; Ultrasonic imaging; United Kingdom > UK; United States > US; China
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers14153719

Although ovarian cancer, a gynecological malignancy, has the highest fatality rate, it still lacks highly specific biomarkers, and the differential diagnosis of ovarian masses remains difficult to determine for gynecologists. Our study aimed to obtain ovarian cancer-specific protein candidates from the circulating small extracellular vesicles (sEVs) and develop a protein panel for ovarian cancer screening and differential diagnosis of ovarian masses. In our study, sEVs derived from the serum of healthy controls and patients with cystadenoma and ovarian cancer were investigated to obtain a cancer-specific proteomic profile. In a discovery cohort, 1119 proteins were identified, and significant differences in the protein profiles of EVs were observed among groups. Then, 23 differentially expressed proteins were assessed using the parallel reaction monitoring in a validation cohort. Through univariate and multivariate logistic regression analyses, a novel model comprising three proteins (fibrinogen gamma gene (FGG), mucin 16 (MUC16), and apolipoprotein (APOA4)) was established to screen patients with ovarian cancer. This model exhibited an area under the receiver operating characteristic curve (AUC) of 0.936 (95% CI, 0.888–0.984) with 92.0% sensitivity and 82.9% specificity. Another panel comprising serum CA125, sEV-APOA4, and sEV-CD5L showed excellent performance (AUC 0.945 (95% CI, 0.890–1.000), sensitivity of 88.0%, specificity of 93.3%, and accuracy of 89.2%) to distinguish malignancy from benign ovarian masses. Altogether, our study provided a proteomic signature of circulating sEVs in ovarian cancer. The diagnostic proteomic panel may complement current clinical diagnostic measures for screening ovarian cancer in the general population and the differential diagnosis of ovarian masses.